Nuvalent's price target raised to $140 from $125 due to positive drug outlook

From Yahoo Finance: 2025-06-25 10:20:00

Leerink raised Nuvalent’s price target to $140 from $125, citing its zidesamtinib drug as best in class in the ROS1 landscape with durability and tolerability. The firm maintains an Outperform rating, believing the drug has the potential to be a blockbuster in ROS1+ tumors.

For real-time, market-moving breaking financial news, visit TheFly. Check out today’s best-performing stocks on TipRanks for more information.

For more details on Nuvalent, visit TipRanks for Disclaimer & Disclosure information and to Report an Issue.



Read more at Yahoo Finance: Nuvalent price target raised to $140 from $125 at Leerink